Literature DB >> 14503853

Intraperitoneal delivery of cholera toxin B subunit enhances systemic and mucosal antibody responses.

Su-Jung Park1, Sung-Ki Chun, Pyeung-Hyeun Kim.   

Abstract

Although cholera toxin (CT) is a potent mucosal adjuvant, its activity in systemic immunity is relatively undocumented. In the present study, we investigated its adjuvant effect on systemic and mucosal antibody responses following intraperitoneal immunization of mice with BSA. CT increased levels of anti-BSA specific IgG1, IgM, and IgA antibodies in the peritoneum and serum, as well as IgA and IgG1 antibodies in the intestinal fluids. The B subunit of CT (CTB) was as potent as CT itself, with potency comparable to that of incomplete Freund's adjuvant. CTB also increased the number of BSA-specific Ig secreting cells in the spleen and mesenteric lymph node, and stimulated expression of B7.2 but not of MHC class II molecules on peritoneal macrophages, particularly in the presence of IFN-gamma. Our results imply that intraperitoneally administered CTB enhances systemic and mucosal antibody responses, in part at least via effects on macrophages.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14503853

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  5 in total

1.  Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis.

Authors:  Constantine Bitsaktsis; Deepak B Rawool; Ying Li; Nitin V Kurkure; Bibiana Iglesias; Edmund J Gosselin
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

2.  Role of CD80 and CD86 in host immune responses to the recombinant hemagglutinin domain of Porphyromonas gingivalis gingipain and in the adjuvanticity of cholera toxin B and monophosphoryl lipid A.

Authors:  Ping Zhang; Janina P Lewis; Suzanne M Michalek; Jannet Katz
Journal:  Vaccine       Date:  2007-06-19       Impact factor: 3.641

Review 3.  Formulation technologies for oral vaccines.

Authors:  R R C New
Journal:  Clin Exp Immunol       Date:  2019-08-08       Impact factor: 4.330

4.  Evaluation of Helicobacter pylori OipA protein as a vaccine candidate and propolis as an adjuvant in C57BL/6 mice.

Authors:  Hengameh Soudi; Tahereh Falsafi; Mohaddeseh Mahboubi; Sara Gharavi
Journal:  Iran J Basic Med Sci       Date:  2021-09       Impact factor: 2.699

5.  Fusion-expressed CTB improves both systemic and mucosal T-cell responses elicited by an intranasal DNA priming/intramuscular recombinant vaccinia boosting regimen.

Authors:  Sugan Qiu; Xiaonan Ren; Yinyin Ben; Yanqin Ren; Jing Wang; Xiaoyan Zhang; Yanmin Wan; Jianqing Xu
Journal:  J Immunol Res       Date:  2014-04-01       Impact factor: 4.818

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.